Clearmind Medicine receives IRB approval for Phase I/IIa trial of CMND-100

Clearmind Medicine (CMND) announced it has received Institutional Review Board approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder. The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100.